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To the Editor—In their commentary on our paper
concerning the use of economic evaluation in deci-
sion making, Hutton and Brown [1] point out that
there are two sides to the problem. That is, while
economic evaluation may need to change, so may
decision making in the British National Health
Service (NHS). This is undoubtedly true, but we
make no excuses for concentrating on one side of
the problem. As health-service researchers, we feel
that our prime responsibility is to improve the 
reliability and relevance of the ﬁndings we produce.
Therefore, it is important, through databases like
NHS Economic Evaluation Database (EED), to 
continue to explore the ways of making economic
studies more accessible, without losing the key 
elements of critical appraisal.
Nevertheless, we agree that it would be fruitful
to examine some of the potential ﬂaws in health-
care decision making. Certainly, we do not accept
decision makers’ views without question. In partic-
ular we share Hutton and Brown’s concern about
the requests for quality scores (for studies), since
this might lead decision makers to undertake even
less critical assessment of research ﬁndings than
they do currently.
We also share Hutton and Brown’s concern
about the fact that the decision makers in our study
questioned the quality of clinical effectiveness data
in economic studies. In particular, we need to ﬁnd
out whether the problem is that economic evalua-
tions lack good-quality data or that good clinical
data were not available at the time the economic
studies were done.
In an abstract presented at the last International
Society for Pharmacoeconomics and Outcomes
Research (ISPOR) Annual Meeting, we showed 
that there is often a long and inexplicable lag
between the publication of the ﬁrst clinical data, or
good quality data (deﬁned as 4 or 5 out of 5, or 2
out of 3 on the Jadad quality checklist) and the sub-
sequent publication of the ﬁrst cost-effectiveness
study [2].
The existence of this lag merits further investi-
gation, but it suggests that there ought to be more
connection between the clinical development plans
for drugs (and other health technologies) and the
strategy for generating economic evidence. It also
suggests that the problem is not the lack of avail-
ability of clinical data. Rather, we suspect that the
shortcomings of the clinical data are made much
more apparent when one attempts to use them in
an economic study.
Decision makers’ concerns about the lack of gen-
eralizability of economic studies are more difﬁcult
to address. Hutton and Brown argue that there
ought to be greater understanding at the local level,
so as to adapt study ﬁndings, and a stronger com-
mitment to fund local studies. However, one is still
left wondering what, if any, generalizable ﬁndings
are communicated by the publication of a cost-
effectiveness study and whether the reporting of
results could be improved so as to make the gener-
alizable messages more self-evident.
Finally, Hutton and Brown point out that health-
service reorganizations, such as the one currently
being undertaken in the British NHS, present
opportunities to rectify some of the problems
related to the use of economic evidence in decision
making. However, many such reorganizations
merely shufﬂe the pack rather than bring about real
change. This is why we need continued research
into the problems of using economic evidence 
in health-care decision making.—Christiane 
Hoffmann, Boyka Stoykova, John Nixon, Julie
Glanville, Kate Misso, Michael Drummond
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* * *
To the Editor—With reference to the editorial by
Dr. Bruno Detournay and colleagues [1]  in response
to our paper on the cost-effectiveness of interferon
beta [2], we have the following comments.
We agree that multiple sclerosis (MS) is a severe
condition with potentially disastrous consequences
for the patient and her family and has major public
health and economic consequences for society. The
concern of decision makers is with the ability of 
currently licensed treatments to avoid or reduce the
burden of the disease.
Modeling is indeed an approach that aims to 
synthesize the best available data to give guidance
to decision makers. If there were certainty over the
© ISPOR 1098-3015/02/$15.00/114 114–116
LETTERS TO THE EDITOR
115Letters to the Editor
costs, outcomes, and beneﬁts of MS treatments,
modeling and extrapolation of data would be
unnecessary. It is noteworthy that the main prob-
lems faced by the economic analyst in MS stem
from the inadequacy of the clinical information
about the disease itself and the longer-term effects
of treatment.
The absence of cohort studies following the evo-
lution of the disease and the use of clinical scales of
uncertain provenance to categorize disease impact
are encountered by economists in many disease
areas. However, overcoming these deﬁciencies takes
time, and if clinicians are willing to make decisions
on the use of treatments on the basis of data that is
currently available, then policymakers must do so
as well.
To assist decision makers, modeling must use the
best available data and adapt the most appropriate
analytical techniques. Because the consequences of
MS are experienced over the patient’s lifetime, a
long time horizon is appropriate for models in this
disease (the recent model produced for the National
Institute for Clinical Excellence [NICE] in England
and Wales used 20 years). That the long-term
impact of current treatments is unknown and, as a
consequence, the later years of the modeled analy-
sis do not change the incremental differences
between treatments should not lead to the choice of
an inappropriate model framework. Long-term
data will eventually be produced. The possibility of
new (possibly more cost-effective) treatments in the
future does not remove the need for decisions to be
made now about reimbursement of current treat-
ments, nor does it preclude the need for sound data
on current treatments to compare with those on
future treatments.
It is very easy to exaggerate the problems of com-
municating the results of models, and the users of
models are becoming more sophisticated. Never-
theless, clear presentation of assumptions, struc-
tures, and data sources is good practice in modeling,
as in my other form of analysis. Clarity, however,
does not always require simplicity.—John Hutton,
Vice President, European Operations.
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